Trastuzumab botidotin

Without a doubt, ADC (Antibody Drug Conjugates) is one of the hottest fields in recent years. In 2022, the global sales exceeded 7 billion US dollars, and the sales of these drugs in the first half of this year have already exceeded 5 billion US dollars. It is expected to break the 10 billion dollar mark for the full year. Currently, 15 ADCs have been approved for marketing. Hundreds of ADCs are under investigation worldwide, and in pursuit of differentiation and increased competitiveness, an increasing number of targets are being developed, including popular targets such as HER2, Trop-2, EGFR, and emerging targets like Nectin-4, B7-H3, and B7-H4. Pharmaceutical giants have also joined in the layout of the ADC pipeline. This year, Pfizer has acquired Seagen for as high as 43 billion US dollars, incorporating its ADC pipeline, including Nectin-4 ADC Padcev, CD30 ADC Adcetris, Zinc transporter LIV-1 ADC Ladiratuzumab vedotin, ITGB6 ADC SGN-B6A and B7H4 ADC SGN-B7H4V. Global Phase III Clinical ADCs under InvestigationApart from the approved ADCs, there are hundreds of ADCs under clinical investigation, covering a increasingly diverse range of targets. Not only do they include popular targets like HER2 and Trop-2, but also emerging targets such as B7-H3, FRα, Nectin-4, and so on. There are several drugs globally that have entered phase III clinical stage. The figure below lists some of the ADCs under phase III clinical investigation. A166 A166 is a HER2 ADC developed by Sichuan Kelun-Biotech Biopharmaceutical, a subsidiary of Sichuan Kelun Pharmaceutical, using the OptiDC platform. By stably proteolytic cleavable valine-citrulline linker, it specifically links to the HER2 antibody site and couples it to Duo-5 (an antimicrotubule agent). It has demonstrated its safety and effectiveness in HER2-positive breast cancer patients. Last year, at the ASCO conference, Sichuan Kelun-Biotech Biopharmaceutical announced the results of a phase I trial of A166 (CTR20181301). The best ORR among all patients in the 4.8 and 6.0 mg/kg groups was 73.91% and 68.57%, respectively, with mPFS of 12.30 and 9.40 months, respectively. Among 23 patients treated at a dose level of 4.8 mg / kg, one patient had confirmed and sustained complete remission for 7+ months[1]. The new drug application for A166 was accepted by the CDE on May 11th, for the treatment of HER2-positive locally advanced, inoperable, recurrent or metastatic breast cancer that has failed second-line and above anti-HER2 treatment. Patritumab deruxtecan Patritumab deruxtecan (HER3-DXd, U3-1402) is the world's first HER3-targeting antibody-drug conjugate (ADC) developed by Daiichi Sankyo, and is currently being investigated for indications such as breast cancer and non-small cell lung cancer (NSCLC). HER3-DXd is created by conjugating the monoclonal antibody patritumab (U3-1287), which targets the extracellular domain of HER3, to the cytotoxic topoisomerase I inhibitor deruxtecan using a maleimidocaproyl-GGFG linker via a cysteine-specific coupling approach, with a drug-to-antibody ratio (DAR) of 8. Structure of HER3-DXdIn an oral presentation at this year's ASCO meeting, Daiichi Sankyo unveiled Part A results of the Phase 2 study of HER3-Dxd in patients with HER2-negative metastatic breast cancer (MBC): the overall response rate (ORR) in the total population was 35%, the clinical benefit rate (CBR) was 48%, and the median duration of response (DOR) was 10.0 months, with a 6-month progression-free survival (PFS) rate of 60%. Clinical results of Part AMore recently, at the 2023 WCLC meeting, Daiichi Sankyo announced the key results of the HERTHENA-Lung01, a pivotal Phase 2 study of HER3-DXd in patients with EGFR-mutated non-small cell lung cancer. Evaluated by blinded independent central review (BICR), in 225 patients with EGFR mutation-positive NSCLC treated with HER3-DXd (5.6mg/kg), a confirmed ORR of 29.8% was observed, including 1 complete response (CR), 66 partial responses (PR), and 99 cases of stable disease (SD). The DOR was 6.4 months, with a disease control rate (DCR) of 73.8%. As of May 18, 2023, the median progression-free survival (PFS) was 5.5 months, and the median overall survival (OS) was 11.9 months. Main results of the HERTHENA-Lung01 trial of HER3-DXdMoreover, Merck (known as MSD outside of the United States and Canada) has recently acquired three ADCs, including HER3-Dxd, with a total purchase price of $22 billion, indicating Merck's significant optimism for the potential of this drug. Datopotamab deruxtecan Datopotamab deruxtecan (Dato-DXd, DS-1062) is a Trop-2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca and Daiichi Sankyo. It is constructed by coupling a recombinant humanized anti-Trop-2 IgG1 antibody to a topoisomerase I inhibitor (DXd) via a tetrapeptide-based cleavable linker designed to reduce cysteine residues on the interchain disulfide bonds of datopotamab. The tetrapeptide-based linker is designed to release DXd following proteolytic processing by lysosomal enzymes, such as cathepsin, upon internalization into cancer cells. On average, the goal is to have an average of four drug-to-antibody ratio (DAR) per antibody molecule. Unlike Trodelvy, the first approved Trop-2 ADC for the treatment of breast cancer, AstraZeneca and Daiichi Sankyo plan to focus on advanced non-small cell lung cancer (NSCLC) as the initial indication for Dato-DXd, positioning it as a potential alternative to chemotherapy in the treatment of NSCLC. Structure of Dato-DXdAt this year's ASCO Annual Meeting, AstraZeneca and Daiichi Sankyo presented study results for Dato-DXd in the treatment of advanced NSCLC from the TROPION-Lung02 study: Dato-DXd combined with durvalumab or Dato-DXd combined with durvalumab plus platinum-based chemotherapy resulted in an objective response rate (ORR) of 38% and 49%, disease control rates (DCR) of 84% and 87%, and progression-free survival (PFS) of 8.3 months and 7.3 months, respectively, in the overall advanced NSCLC population. In the first-line treatment population, the ORR for Dato-DXd combined with durvalumab or with durvalumab plus platinum-based chemotherapy was 50% and 57%, respectively, with a DCR of 91% for both combinations, and the median duration of response (DOR) had not yet been reached. These results further confirm the significant efficacy and good safety profile of Dato-DXd combined with durvalumab ± platinum-based chemotherapy in first-line or previously treated advanced NSCLC patients without actionable genomic alterations. However, Dato-DXd has also encountered safety issues. Although the TROPION-Lung01 trial met its primary clinical endpoint, serious safety concerns arose, including cases of interstitial lung disease and Grade 5 adverse events leading to death due to drug-related adverse reactions. This news had a significant impact on both AstraZeneca and Daiichi Sankyo, causing their stock prices to drop by 8% and 15% respectively on the day of the announcement. Global Phase II Clinical ADCs under Investigation DB-1305 DB-1305 is a Trop-2 targeted ADC developed by Yingen Biopharmaceutical based on its proprietary Duality ImmunoToxin Antibody Conjugate (DITAC) platform, coupling a Trop-2 antibody to an innovative topoisomerase I inhibitor, P1021, through an enzymatically cleavable tetrapeptide linker. In June 2022, DB-1305 initiated an open-label, multi-center, multi-dose, phase 1/2a study (NCT05438329), which included a dose-escalation phase 1 in pretreated patients with advanced solid tumors and a dose-expansion phase 2a. As of December 19, 2022, 20 patients have participated in the dose-escalation portion of the study. Currently, Yingen Biopharmaceutical is co-developing, producing, and commercializing DB-1305 in partnership with BioNTech. This collaboration follows BioNTech's acquisition of two ADC products from Yingen Biopharmaceutical for $1.67 billion in April 2023, making DB-1305 the third product the two companies are jointly advancing. 9MW2821 9MW2821 is an ADC (Antibody-Drug Conjugate) targeting Nectin-4, developed by Jiangsu Maiweikang New Drug Research and Development Co. It received domestic clinical approval in China in October 2021, with indications including urothelial carcinoma, breast cancer, lung cancer, and several other solid tumors. 9MW2821 is produced by employing inter-chain disulfide drug conjugation technology to link a humanized antibody with the cytotoxic payload monomethyl auristatin E (MMAE). Structure and Mechanism of Action of 9MW2821The ADC 9MW2821 is currently undergoing Phase 1/2 clinical trials (NCT05216965 and NCT05773937) in patients with advanced solid tumors, aiming to evaluate the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and immunogenicity of 9MW2821 administered intravenously. Global Phase I Clinical ADCs under Investigation Mirzotamab clezutoclax  Mirzotamab clezutoclax (ABBV-155; Mirzo-C) is a B7-H3-targeted Antibody-Drug Conjugate (ADC) developed by AbbVie, comprising three components: an anti-B7-H3 monoclonal antibody, a cleavable linker, and a BCL-XL inhibitor payload. Specific targeting of BCL-XL has demonstrated synergy with other anticancer drugs in preclinical models. At this year's ASCO conference, AbbVie released the results of a Phase 1 open-label study (NCT03595059) for ABBV-155, evaluating the efficacy of ABBV-155 in combination with taxane-based chemotherapy. As of November 18, 2022, a total of 78 patients had been enrolled (small cell lung cancer n=14; non-small cell lung cancer n=36; breast cancer n=28). In terms of efficacy, the confirmed objective response rate (cORR) for the SCLC cohort was 0%, with a 0% partial response (PR) rate; the NSCLC cohort had a cORR of 11% and a PR rate of 36%; the breast cancer cohort exhibited a cORR of 18% and PR rate of 36%. Overall, ABBV-155, whether used as a monotherapy or in combination with docetaxel, displayed favorable tolerability. Clinical Results of ABBV-155SGN-B6A SGN-B6A is an antibody-drug conjugate (ADC) developed by Seagen, targeting integrin β-6 (ITGB6) to deliver the clinically validated potent payload monomethyl auristatin E (MMAE) to cancer cells. The antibody component of SGN-B6A is specific for integrin β-6 and does not bind to other members of the α-v family. SGN-B6A mediates anti-tumor activity through MMAE-induced cytotoxicity, bystander effects, and immunogenic cell death. Structure and Selectivity of SGN-B6AAt this year's ASCO meeting, Antoine and colleagues presented the results of a phase 1 clinical trial (NCT04389632) for SGN-B6A. As of December 14, 2022, 148 patients were treated with SGN-B6A, including 88 patients in part A and 60 patients in part B of the study, with enrollment for part A completed. SGN-B6A demonstrated a manageable safety profile and showed encouraging preliminary anti-tumor activity with dose-escalated durability of response in a heavily pretreated population. Dose-expansion cohorts of part B for non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and head and neck squamous cell carcinoma (HNSCC) are currently ongoing. Phase 1 Clinical Trial Results of SGN-B6ANumerous antibody-drug conjugate (ADC) therapies have been successfully developed to date, benefiting tens of thousands of cancer patients. As of now, there are 15 ADCs that have been globally approved for marketing. The market presence of these ADCs, along with the impressive clinical performance of various ADCs, has garnered increased attention in this field. In addition, there are several hundred ADCs currently under research around the world, targeting markers such as HER2, Trop-2, B7-H3, c-Met, and EGFR, among others. This article summarizes a portion of the ADCs in clinical research and briefly introduces some of the typical compounds among them, with the belief that more ADCs will be approved and reach the market in the near future.

DelveInsight's bladder cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for bladder cancer treatment. LAS VEGAS, Aug. 23, 2022 /PRNewswire/ -- DelveInsight's ' Bladder Cancer Pipeline Insight 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline bladder cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the bladder cancer pipeline domain. Key Takeaways from the Bladder Cancer Pipeline Report DelveInsight's bladder cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for bladder cancer treatment. Leading bladder cancer companies such as CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, Keythera Pharmaceuticals, Quadriga Biosciences, Inc., NeoTX Therapeutics Ltd., Mirati Therapeutics, NGM Biopharmaceuticals, TransThera Biosciences, Ocellaris Pharma, Palleon Pharmaceuticals, Medicenna Therapeutics, Klus Pharma, Novartis, Toray Industries, Carisma Therapeutics, Avacta Life Sciences Ltd, Seagen Inc., Elevation Oncology, Corvus Pharmaceuticals, ADC Therapeutics S.A., IO Biotech, Byondis B.V., Takara Bio, Seven and Eight Biopharmaceuticals, Dragonfly Therapeutics, InnoCare Pharma, and others are evaluating novel bladder cancer drugs candidate to improve the treatment landscape. Key bladder cancer pipeline therapies in various stages of development include CG0070, ADSTILADRIN, Nivolumab, Catumaxomab, N-803, alpha1H, APL-1202, PF-07225570, HX008, TARA-002, CPX-POM, EG-70, eRapa, TLD-1433, VAX014, Erdafitinib, Enfortumab vedotin, RC48-ADC, TAS 102, UGN-102, FL-101, AU-011, Tislelizumab, Pemigatinib, Infigratinib, Trilaciclib, AN0025, KHK2455, IPI-549, SHR-1501, HC-7366, IK-175, ado-trastuzumab emtansine, FPI-1966, GI-101, SO-C101, CPL304110, MRx0518, KF-0210, QBS10072S, Naptumomab Estafenatox, Sitravatinib, NGM120, TT-00420, OC-001, E-602, MDNA11, A166, Spartalizumab, TRK-950, CT-0508, AVA6000, SEA-TGT, Seribantumab, CPI-006, ADCT-301, IO 102, SYD985, TBI-1301, BDB001, DF1001, ICP-192, and others. In July 2022, The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease. ImmunityBio, a leading clinical-stage immunotherapy company, filed the BLA based on positive results from a series of studies of the investigational treatment, including the ongoing QUILT 3.032 trial. The Prescription Drug User Fee Act (PDUFA) target action date is May 23, 2023. In June 2022, CG Oncology announced the interim data on two ongoing clinical studies to be presented at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.The first poster presentation reports on efficacy and safety data from a global Phase 2 study (CORE1) of CG0070 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). The second poster presentation centers on a Phase 1b/2 study (CORE2) of CG0070 in combination with OPDIVO®(nivolumab), as a neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients. In May 2022, Asieris Pharmaceuticals announced that the ANTICIPATE Study will be presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting on June 3-7, 2022, in Chicago. This is a study of taking oral APL-1202 in combination with BeiGene's tislelizumab compared to just taking tislelizumab alone as neoadjuvant therapy (NAC) in patients with muscle invasive bladder cancer (MIBC). In March 2022, Protara Therapeutics, Inc. announced that the Company had dosed the first patient in ADVANCED-1, its Phase 1 clinical trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC). In January 2022, Vaxiion Therapeutics, announced the U.S. Food and Drug Administration had cleared the company's Investigational New Drug application (IND) for VAX014 for investigational use in the intralesional treatment of solid tumors refractory to standard treatment options. VAX014 is a first-in-class recombinant bacterial minicell-based oncolytic immunotherapy. In December 2021, LintonPharm Co., Ltd., announced that the first patient had been dosed in the Company's Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). Request a sample and discover the recent advances in bladder cancer treatment @ Bladder Cancer Pipeline Report The bladder cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage bladder cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the bladder cancer pipeline landscape. Bladder Cancer Overview Bladder cancer usually starts in the cells that line the inside of the bladder. It typically affects adults over the age of 70 and is more common in men. Bladder cancer is the fifth most prevalent type of cancer in the general population and the fourth most common in males. When detected early, bladder cancer usually responds well to bladder cancer treatment. Smoking is among the most common bladder cancer causes. Blood in the urine is usually the first sign of bladder cancer. Other bladder cancer symptoms may include urine pain or burning, as well as a change in urinary habits. This can include frequent urination or the need to urinate but being unable to do so. The tests used for bladder cancer diagnosis include biopsy, cystoscopy, urine cytology, imaging tests, and others. Find out more about bladder cancer drugs in development @ Bladder Cancer Drugs A snapshot of the Bladder Cancer Pipeline Drugs mentioned in the report: Learn more about the novel and emerging bladder cancer pipeline therapies @ Bladder Cancer Clinical Trials Bladder Cancer Therapeutics Assessment The bladder cancer pipeline report proffers an integral view of the bladder cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Bladder Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Parenteral, Oral, Intravenous, Subcutaneous, Intramuscular Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine Therapeutics Assessment By Mechanism of Action: Cell death stimulants, Granulocyte macrophage colony stimulating factor agonists, Interleukin-15 receptor agonists, DNA synthesis inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Gene transference, IFNA2B expression stimulants, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants Key Bladder Cancer Companies: CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co.,Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, Keythera Pharmaceuticals, Quadriga Biosciences, Inc., NeoTX Therapeutics Ltd., Mirati Therapeutics, NGM Biopharmaceuticals, TransThera Biosciences, Ocellaris Pharma, Palleon Pharmaceuticals, Medicenna Therapeutics, Klus Pharma, Novartis, Toray Industries, Carisma Therapeutics, Avacta Life Sciences Ltd, Seagen Inc., Elevation Oncology, Corvus Pharmaceuticals, ADC Therapeutics S.A., IO Biotech, Byondis B.V., Takara Bio, Seven and Eight Biopharmaceuticals, Dragonfly Therapeutics, InnoCare Pharma, and others Key Bladder Cancer Pipeline Therapies: CG0070, ADSTILADRIN, Nivolumab, Catumaxomab, N-803, alpha1H, APL-1202, PF-07225570, HX008, TARA-002, CPX-POM, EG-70, eRapa, TLD-1433, VAX014, Erdafitinib, Enfortumab vedotin, RC48-ADC, TAS 102, UGN-102, FL-101, AU-011, Tislelizumab, Pemigatinib, Infigratinib, Trilaciclib, AN0025, KHK2455, IPI-549, SHR-1501, HC-7366, IK-175, ado-trastuzumab emtansine, FPI-1966, GI-101, SO-C101, CPL304110, MRx0518, KF-0210, QBS10072S, Naptumomab Estafenatox, Sitravatinib, NGM120, TT-00420, OC-001, E-602, MDNA11, A166, Spartalizumab, TRK-950, CT-0508, AVA6000, SEA-TGT, Seribantumab, CPI-006, ADCT-301, IO 102, SYD985, TBI-1301, BDB001, DF1001, ICP-192, and others. Dive deep into rich insights for bladder cancer drugs, visit @ Bladder Cancer Treatment Table of Contents For further information on the bladder cancer pipeline therapeutics, reach out @ New Drug for Bladder Cancer Treatment Related Reports Bladder Cancer Market Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bladder cancer companies including RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, among others. Bladder Cancer Epidemiology Forecast Bladder Cancer Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted bladder cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Muscle Invasive Bladder Cancer Pipeline Muscle Invasive Bladder Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key muscle invasive bladder cancer companies, including SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, among others. Muscle Invasive Bladder Cancer Market Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key muscle invasive bladder cancer companies including SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, among others. Non Muscle Invasive Bladder Cancer Pipeline Non Muscle Invasive Bladder Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non muscle invasive bladder cancer companies, including Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., among others. Non Muscle Invasive Bladder Cancer Market Non Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non muscle invasive bladder cancer companies including Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., among others. Other Trending Reports Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market Related Healthcare Blogs Bladder Cancer Highlights From ASCO GU 2022 Non Small Cell Lung Cancer Market Outlook Rare Cancers Market Domain About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP